- Market Capitalization, $K 223,166
- Shares Outstanding, K 149,776
- Annual Sales, $ 24,290 K
- Annual Income, $ -24,280 K
- 60-Month Beta 0.32
- Price/Sales 9.19
- Price/Cash Flow N/A
- Price/Book 6.35
|Period||Period Low||Period High||Performance|
| || |
-0.40 (-21.98%)since 06/19/19
| || |
+0.03 (+2.16%)since 04/18/19
| || |
-0.65 (-31.40%)since 07/19/18
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter...
According to Stratistics MRC, the Global Translational Regenerative Medicines Market is growing at a CAGR of 13.9% from 2017 to 2026. Factors such as the increasing prevalence of degenerative diseases,...
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van...
Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year's International Society for Cell and Gene Therapy (ISCT) conference taking place May 29 - June 2, 2019 in...
Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University...
Athersys, Inc. (Nasdaq: ATHX) announced today that its clinical program evaluating MultiStem(R) cell therapy for the treatment of Acute Respiratory Distress Syndrome ("ARDS") has received Fast Track designation...
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Athersys, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time.
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Athersys, Inc. (NASDAQ:ATHX), Crescent...
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.
Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.